News & Events zu LENZ Therapeutics Inc (LENZ)LENZLENZ Therapeutics Inc

Company Reports Q3 Revenue of $3.38M, Below Consensus

Reports Q3 revenue $3.38M, consensus $4.2M. The company's cash, cash equivalents and marketable securities were $197.3M as of September 30. The company said, "Our strong third-quarter results demonstrate continued progress in the commercialization of VIZZ, with product sales growth of 50%, increasing patient adoption and encouraging refill rates. We view these as promising indicators of our positive trajectory in this emerging market. We are focusing our commercial organization and investment on initiatives we believe will most effectively increase consumer awareness, access and adoption, while improving capital efficiency and supporting VIZZ's continued growth."

Lenz Therapeutics CEO Eef Schimmelpennink to Transition on December 1

Lenz Therapeutics announced that Eef Schimmelpennink, its President and Chief Executive Officer, will transition from his role effective December 1. Dan Chevallard, currently Chief Financial Officer, has been appointed Interim President and CEO, effective December 1. "Schimmelpennink will lead the organization through the reorganization and support a seamless leadership transition by continuing to serve as a strategic advisor to the Company into 2027," the company said in a statement.

LENZ Therapeutics Q2 Revenue Reaches $5.49M, Exceeds Expectations

Reports Q2 revenue $5.49M, consensus $2.38M. "We are encouraged by the early refill behavior we are seeing with VIZZ. The majority of ePharmacy patients have purchased multiple monthly packs since launch, and among those patients, our Q4 2025 and Q1 2026 cohorts are tracking to average annualized utilization of five packs per patient. These trends reinforce the value VIZZ is delivering in the real world," said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. "Our focus is now on bringing more consumers into the category and making access as seamless as possible. Through telehealth, eligible consumers can be evaluated online by an independent licensed eye care professional and, if prescribed, receive VIZZ at home. Together with our national 'Tired of Reading Glasses' campaign, telehealth is designed to more readily convert awareness into adoption. While it is still early, the initial indicators are encouraging, and we believe we are building the foundation for sustained growth driven by consumers."